医学临床研究
  2025年6月14日 星期六           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2023, Vol. 40 Issue (8): 1214-1217    DOI: 10.3969/j.issn.1671-7171.2023.08.027
  论著 本期目录 | 过刊浏览 | 高级检索 |
不同剂量替格瑞洛对急性心肌梗死行PCI治疗后再缺血患者的临床疗效
张会琴1, 王智刚2*, 王小妮2
1.延安大学咸阳医院心血管内科,陕西 咸阳 712000;
2.西安国际医学中心医院心血管内科,陕西 西安 710100
Application of Different Doses of Tigrillo in Patients with Acute Myocardial Infarction after Percutaneous Coronary Intervention with Reischemia
ZHANG Hui-qin, WANG Zhi-gang, WANG Xiao-ni
Department of Cardiovascular Medicine,Xianyang Hospital of Yan'an University,Xianyang Shaanxi 712000
全文: PDF (1193 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨不同剂量替格瑞洛对急性心肌梗死(AMI)行经皮冠状动脉介入术(PCI)治疗后再缺血患者的临床疗效。【方法】选择2020年4月至2021年11月于延安大学咸阳医院行PCI的治疗的64例AMI患者,根据治疗方法不同将其分为观察组和对照组,每组32例。比较两组治疗前后血小板功能[血小板聚集率、血小板计数、酶体膜糖蛋白63(CD63)、α颗粒膜糖蛋白62p(CD62p)]、冠状动脉血流参数[收缩期血流峰值(SPV)、舒张期血流峰值(DPV)、冠脉血流储备(CFVR)]、心肌损伤指标[缺血修饰白蛋白(IMA)、心肌肌钙蛋白I(cTnI)、肌红蛋白(Mb)、肌酸激酶同工酶(CK-MB)]、炎症因子[超敏C反应蛋白(hs-CRP)、细胞间黏附分子-1(ICAM-1)、巨噬细胞衍生趋化因子(MDC)、白介素-10(IL-10)]及治疗后不良反应发生率。【结果】治疗后,两组患者血小板聚集率、血小板计数、CD63、CD62p均低于治疗前,且观察组低于对照组(P<0.05);两组患者DPV、SPV、CFVR均高于治疗前,且观察组高于对照组(P<0.05);两组患者IMA、cTnI、Mb、CK-MB水平均低于治疗前,且观察组低于对照组(P<0.05);两组hs-CRP、ICAM-1、MDC、IL-10水平低于治疗前,且观察组低于对照组(P<0.05)。观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。【结论】负荷剂量替格瑞洛治疗AMI患者,可改善PCI术后再缺血患者血小板功能、冠状动脉血流,减轻心肌损伤,降低炎症因子水平,对改善患者预后具有重要意义。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
张会琴
王智刚
王小妮
关键词 心肌梗死/外科学急性病替格瑞洛/投药和剂量血管成形术,气囊,冠状动脉    
Abstract:【Objective】To investigate the clinical efficacy of different doses of Tigrillo in patients with acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI) for reperfusion.【Methods】A total of 64 AMI patients who underwent PCI surgery Xianyang Hospital of Yan&apos;an University from April 2020 to November 2021 were selected and divided into an observation group and a control group based on different treatment methods,with 32 patients in each group. Comparison of the two groups before and after treatment was conducted including platelet function [Platelet aggregation rate,platelet count,enzyme membrane glycoprotein 63 (CD63) α Granular membrane glycoprotein 62p (CD62p)],coronary artery blood flow parameters [Peak systolic blood flow (SPV),peak diastolic blood flow (DPV),coronary flow reserve (CFVR)],myocardial injury indicators[Ischemic modified albumin (IMA),cardiac troponin I (cTnI),myoglobin (Mb),creatine kinase isoenzyme (CK-MB) ],inflammatory factors [Hypersensitivity C-reactive protein (hs-CRP),intercellular adhesion molecule-1 (ICAM-1),macrophage derived chemokine (MDC),interleukin-10 (IL-10)],and the incidence of adverse reactions after treatment.【Results】After treatment,the platelet aggregation rate,platelet count,CD63,and CD62p in both groups of patients were lower than before treatment,and the observation group was lower than the control group (P<0.05); The DPV,SPV,and CFVR of both groups of patients were higher than before treatment,and the observation group was higher than the control group (P<0.05); The levels of IMA,cTnI,Mb,and CK-MB in both groups of patients were lower than before treatment,and the observation group was lower than the control group (P<0.05); The levels of hs-CRP,ICAM-1,MDC,and IL-10 in both groups were lower than before treatment,and the observation group was lower than the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).【Conclusion】The treatment of AMI patients with load dose Tigrillo can improve platelet function,coronary artery blood flow,alleviate myocardial injury,and reduce the expression level of inflammatory factors in patients with reperfusion after PCI,which is of great significance for improving patient prognosis.
Key wordsMyocardial Infarction/SU    Acute Disease    Ticagrelor/AD    Angioplasty,Balloon,Coronary
收稿日期: 2022-07-28     
中图分类号:  R542.22  
通讯作者: *E-mail:wangzhigang4211970@163.com   
引用本文:   
张会琴, 王智刚, 王小妮. 不同剂量替格瑞洛对急性心肌梗死行PCI治疗后再缺血患者的临床疗效[J]. 医学临床研究, 2023, 40(8): 1214-1217.
ZHANG Hui-qin, WANG Zhi-gang, WANG Xiao-ni. Application of Different Doses of Tigrillo in Patients with Acute Myocardial Infarction after Percutaneous Coronary Intervention with Reischemia. JOURNAL OF CLINICAL RESEARCH, 2023, 40(8): 1214-1217.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.08.027     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I8/1214
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn